View:
United States securities and exchange commission logo
June 18, 2024
Leon O. Moulder, Jr.
Chief Executive Officer
Zenas BioPharma, Inc.
1000 Winter Street
North Building, Suite 1200
Waltham, MA 02451
Re: Zenas BioPharma,
Inc.
Amendment No. 2 to
Draft Registration Statement on Form S-1
Submitted June 14,
2024
CIK No. 0001953926
Dear Leon O. Moulder:
We have reviewed your amended draft registration statement and have
the following
comment.
Please respond to this letter by providing the requested
information and either submitting
an amended draft registration statement or publicly filing your
registration statement on
EDGAR. If you do not believe a comment applies to your facts and
circumstances or do not
believe an amendment is appropriate, please tell us why in your
response.
After reviewing the information you provide in response to this
letter and your amended
draft registration statement or filed registration statement, we may
have additional comments.
Amendment No. 2 to Draft Registration Statement on Form S-1
Prospectus Summary
Our Obexelimab Program, page 2
1. We note your response
to prior comment 1. We also note that disclosure in this section
continues to state
obexelimab was well tolerated in five completed clinical trials including
trials that used
intravenous infusion for the delivery of your product candidate. Please
balance this statement
by clarifying that you have observed serious adverse events in trials
of obexelimab
administered through intravenous infusion.
Leon O. Moulder, Jr.
FirstName LastNameLeon O. Moulder, Jr.
Zenas BioPharma, Inc.
Comapany
June NameZenas BioPharma, Inc.
18, 2024
June 18,
Page 2 2024 Page 2
FirstName LastName
Please contact Li Xiao at 202-551-4391 or Angela Connell at 202-551-3426
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Tyler Howes at 202-551-3370 or Chris Edwards at 202-551-6761 with any other
questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Nicholas Roper, Esq.